Our Mission

We make personalized in-silico tests reliable and affordable for large-scale cancer screening; bridging the gap between first-line mass screening tests (e.g., a blood test) that generate many false positives and more invasive, costly diagnostic tests (e.g., a biopsy).

Our Story

Although cancer research has made tremendous progress over the last decade, mass screening detection tools are limited and remain insufficient. We have decided to bring together state-of-the-art research on complexity, mathematics, physics, economics, and biology to bridge the screening gap.

It started back in 2013. While studying the behavior of financial bubbles, we realized that the latest tools, designed to predict financial returns could be used for predictions in other fields. When a friend of ours got diagnosed with prostate cancer that summer, we went back to the drawing table.

Teaming up with the CHRU Nancy, we eventually developed PROSTia. The screening test was built using an innovative machine-learning approach that allowed us to keep it cost-effective. It was validated on a large retrospective cohort of 34,000 patients and is now used by urologists.

OUr Timeline

Where we come from

Where we are now

OUr Awards

  • Healthcare Week Luxembourg - Start-up of the Year 2024

  • La Nuit des Caducées / ESCP Business School - Bronze Award “AI & Healthcare” 2024

  • Trophées de la Santé de L’Est Républicain 2023

  • BioFit 2022 - Runner-up

  • City Healthcare 2022 - CHRU Nancy Award

  • OncoStart 2022 - “Patient Care” Award